Satellos Bioscience Inc.
Satellos Bioscience Inc.
- Market cap
- $7.32M
Your view on MSLE
Overview
What the company does, where it operates, and who runs it.
About Satellos Bioscience Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank Gleeson
- Headquarters
- Royal Bank Plaza, Toronto, ON, CA
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Frank Gleeson
- Headquarters
- Royal Bank Plaza, Toronto, ON, CA
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease.
The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Satellos Bioscience Inc.. Starting points for Satellos Bioscience Inc.: EPS -$1.91, beta 1.17 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Satellos Bioscience Inc.. Trailing twelve-month EPS for Satellos Bioscience Inc. stands at -$1.91. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
1 rating- Strong Buy0
- Buy1
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.57 | −$0.56 | −$2.19 | −$2.27 |
| Lowest estimate | −$0.67 | −$0.56 | −$2.54 | −$2.97 |
| Highest estimate | −$0.45 | −$0.56 | −$1.37 | −$1.41 |
| Number of analysts | 3 | 2 | 4 | 5 |
| A year ago | — | −$0.53 | −$20.401 | — |
| Growth vs a year ago | — | −5.0% | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Lowest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Highest estimate | $0.00 | $0.00 | $0.00 | $0.00 |
| Number of analysts | 0 | 0 | 0 | 0 |
| A year ago | — | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Satellos Bioscience Inc.. Satellos Bioscience Inc. has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ZLDAFZelira Therapeutics Limited | Healthcare | OTC | $5.0M | ||
| ZLDPFZealand Pharma A/S | Healthcare | OTC | $4.0B | ||
| ZNTLZentalis Pharmaceuticals, Inc. | Healthcare | NASDAQ | $133.6M | ||
| ZURAZura Bio Limited | Healthcare | NASDAQ | $89.6M | ||
| ZVRAZevra Therapeutics, Inc. | Healthcare | NASDAQ | $521.3M | ||
| ZVSAZyVersa Therapeutics, Inc. | Healthcare | OTC | $1.1M | ||
| ZYMEZymeworks Inc. | Healthcare | NASDAQ | $1.8B | ||
| VSBCVitaSpring Biomedical Co. Ltd. | Healthcare | OTC | $2.3M | ||
| VSTMVerastem, Inc. | Healthcare | NASDAQ | $797.7M | ||
| VTGNVistaGen Therapeutics, Inc. | Healthcare | NASDAQ | $7.6M | ||
| VTIAFFamiCord AG | Healthcare | OTC | $111.1M | ||
| VTVTvTv Therapeutics Inc. | Healthcare | NASDAQ | $61.3M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Satellos Bioscience Inc., and how their positions are changing. At a $7.3M market value, institutional positions materially move Satellos Bioscience Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Satellos Bioscience Inc.. Coverage tracks Satellos Bioscience Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Satellos Bioscience Inc.